• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Sulthiame may be a safe and effective medication for severe obstructive sleep apnea

byRaahulan RathagirishnanandAvneesh Bhangu
December 19, 2022
in Chronic Disease, Wellness
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial, sulthiame was shown to be a safe oral medication that can improve sleep apnea symptoms.

2. However, the medication sulthiame was associated with more adverse events, such as paresthesia and headaches, compared to placebo.

Evidence Rating Level: 2 (Good)

Obstructive sleep apnea (OSA) is a condition that’s associated with a range of cardiometabolic diseases, including hypertension, arrhythmia, stroke, and diabetes. The main treatment for OSA is continuous positive airway pressure therapy (CPAP), but this is not always effective due to patient adherence. The drug sulthiame, (STM) has been shown to inhibit the enzyme carbonic anhydrase, which has been implicated in one of the main pathological mechanisms of OSA. However, the safety and efficacy of this drug has not been tested in patients with OSA.

This randomized, placebo-controlled, double-blind dose-guiding study was designed to evaluate safety and tolerability of STM in patients with moderate and severe OSA who cannot comply with CPAP therapy. The study involved five consecutive dose escalation cohorts over 4 weeks of treatment, with 68 patients randomized to receive either STM or placebo. Patients were included if they were between 18 and 75 years, had a body mass index between 20 and 35, an Epworth Sleepiness Scale score of at least 6, and had an apnea-hypopnea index greater than 15, corresponding to moderate to severe OSA. Sleep was assessed using polysomnography and patient-reported outcomes were also collected.

Results demonstrated that STM was safe and well tolerated amongst patients with moderate and severe OSA, with no severe adverse events (AEs) attributed to the medication, in keeping with the known safety profile of STM. Specifically, a 200 mg dose had a more favorable tolerability profile compared to 400 mg. The number of AEs were higher in the STM treatment group than placebo; however, commonly reported AE’s including paresthesia’s and headaches were generally short lasting and mild. Compared to the placebo, the apnea-hypoxia was significantly reduced in the STM group. Sleep efficacy and latency were also improved with STM administration. However, this study was limited by its short study period of 4 weeks and the exploration of only 2 doses. Nonetheless, this study provides evidence that the safety profile is acceptable and can improve OSA symptoms.

RELATED REPORTS

Time-restricted eating does not confer changes in sleep, mood, or quality of life

Short sleep duration associated with increased risk of diabetes

Tirzepatide reduces obstructive sleep apnea symptoms and associated risks

Click to read the study in American Journal of Respiratory and Critical Care Medicine 

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Obstructive Sleep ApneaOSAsleepsulthiamewellness
Previous Post

2 Minute Medicine Rewind December 19, 2022

Next Post

Double embryo transfer may be associated with neonatal risks

RelatedReports

Provision of medically-tailored meals linked with lower admissions and medical spending
Chronic Disease

Time-restricted eating does not confer changes in sleep, mood, or quality of life

July 4, 2025
Career Development

Short sleep duration associated with increased risk of diabetes

March 14, 2025
Admission may not be needed following sleep apnea surgery
Chronic Disease

Tirzepatide reduces obstructive sleep apnea symptoms and associated risks

October 10, 2024
Low free sugar diet reduces hepatic steatosis in nonalcoholic fatty liver disease in adolescent males
Chronic Disease

Poor sleep and elevation of liver function biomarkers may be predictive of liver cancer

July 6, 2024
Next Post
Assisted conception not associated with increased pediatric cancer risk

Double embryo transfer may be associated with neonatal risks

Choosing Wisely campaign releases recommendations in newborn medicine

Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma

Time from symptom onset may not predict infarct volume in stroke

Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
  • Mazdutide significantly reduces weight in adults with overweight or obesity
  • Oral vancomycin may be effective for pouchitis in inflammatory bowel disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.